The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The 31-GEP to identify patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system.
 
Merve Hasanov
Honoraria - Curio Science (I)
Consulting or Advisory Role - Eisai (I); Pfizer (I); Telix Pharmaceuticals (I)
 
Brian Martin
Employment - Castle Biosciences
Stock and Other Ownership Interests - Castle Biosciences
Research Funding - Castle Biosciences
Travel, Accommodations, Expenses - Castle Biosciences
 
Elshad Hasanov
Honoraria - Curio Science
Consulting or Advisory Role - Eisai; Pfizer; Telix Pharmaceuticals
 
Richard Cheng Han Wu
Consulting or Advisory Role - Tempus
Research Funding - Iovance Biotherapeutics (Inst); Regeneron (Inst); Xilio Therapeutics (Inst)
 
Matthew S. Goldberg
Employment - Castle Biosciences
Stock and Other Ownership Interests - Castle Biosciences; PathPresenter
Consulting or Advisory Role - Castle Biosciences
 
Robert W. Cook
Employment - Castle Biosciences
Stock and Other Ownership Interests - Castle Biosciences
Patents, Royalties, Other Intellectual Property - Castle Biosciences related patents
Travel, Accommodations, Expenses - Castle Biosciences
 
Kari Lynn Kendra
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); ISTARI Oncology (Inst); Merck (Inst); Novartis (Inst)
 
Abel Jarell
Honoraria - Abbvie; Arcutis Biotherapeutics; Bristol-Myers Squibb; Castle Biosciences; Dermira; Incyte; Leo Pharma; Lilly ICOS LLC; Novartis; Pfizer; Sanofi/Regeneron; UCB; UCB
Consulting or Advisory Role - Abbvie; Arcutis Biotherapeutics; Bristol-Myers Squibb; Castle Biosciences; Dermira; Incyte; Leo Pharma; Novartis
Speakers' Bureau - Abbvie; Arcutis Biotherapeutics; Castle Biosciences; Lilly ICOS; Novartis; Pfizer
Research Funding - Abbvie (Inst); Almirall (Inst); Alumis; Alumis (Inst); Arcutis Biotherapeutics; Arcutis Biotherapeutics (Inst); Asana Biosciences (Inst); Castle Biosciences (Inst); Concert Pharmaceuticals (Inst); Dermira (Inst); Foamix; Foamix (Inst); Incyte (Inst); Janssen; Janssen (Inst); Lilly ICOS (Inst); Takeda; Takeda (Inst); UCB (Inst); Vivex Biomedical Inc. (Inst)